Vivos Therapeutics (VVOS) Assets Average (2021 - 2026)

Vivos Therapeutics (VVOS) has reported Assets Average for 6 consecutive years, with $24.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average rose 31.82% year-over-year to $24.6 million in Q2 2026; TTM through Jun 2026 was $24.6 million, a 31.82% increase from a year earlier, with the FY2025 full-year figure at $20.2 million, up 55.44% from the prior year.
• Assets Average was $24.6 million for Q2 2026 at Vivos Therapeutics, down from $25.1 million in the prior quarter.
• Over five years, Assets Average peaked at $31.6 million in Q1 2022 and troughed at $10.5 million in Q4 2023.
• A 5-year average of $18.8 million and a median of $15.8 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average slumped 57.01% in 2022 and soared 88.94% in 2026, its largest moves.
• Over 5 years, Assets Average stood at $16.1 million in 2022, then plunged by 34.47% to $10.5 million in 2023, then surged by 45.54% to $15.3 million in 2024, then surged by 65.83% to $25.4 million in 2025, then slipped by 3.17% to $24.6 million in 2026.
• The last three Assets Average figures came in at $24.6 million (Q2 2026), $25.1 million (Q1 2026), and $25.4 million (Q4 2025), per Business Quant data.